Skip to main content

Table 1 Characteristics of 15 included studies

From: Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis

First Author Year Sample Size Interventions Platinum-resistant NOS score
Hamanishi [9] 2015 20 Nivolumab Yes 8
Disis [10] 2019 125 Avelumab NA 8
Konstantinopoulos [11] 2019 60 Pembrolizumab + niraparib Yes 8
Liu [12] 2019 9 Atezolizumab NA 8
Liu [13] 2019 38 Nivolumab + bevacizumab NA 8
Matulonis [5] 2019 376 Pembrolizumab NA 8
Varga [14] 2019 26 Pembrolizumab NA 8
Walsh [6] 2019 14 Pembrolizumab + cisplatin + gemcitabine Yes 5
Lampert [15] 2020 35 Durvaluamb + olaparib NA 7
Lee [16] 2020 23 Pembrolizumab + pegylated liposomal doxorubicin Yes 7
Moroney [17] 2020 12 Atezolizumab + bevacizumab Yes 7
O'Cearbhaill [18] 2020 40 Durvalumab + pegylated liposomal doxorubicin Yes 5
Zamarin [19] 2020 27 Pembrolizumab + folate receptor alpha vaccine Yes 9
Zamarin [20] 2020 100 Nivolumab + ipilimumab vs nivolumab NA 7
Zsiros [7] 2020 40 Pembrolizumab + bevacizumab + cyclophosphamide NA 8